CN109232748B - Cyclic hybrid peptides conjugated with multi-site modified enkephalins and neurotensin (8-13) and their synthesis methods and applications - Google Patents
Cyclic hybrid peptides conjugated with multi-site modified enkephalins and neurotensin (8-13) and their synthesis methods and applications Download PDFInfo
- Publication number
- CN109232748B CN109232748B CN201811126681.0A CN201811126681A CN109232748B CN 109232748 B CN109232748 B CN 109232748B CN 201811126681 A CN201811126681 A CN 201811126681A CN 109232748 B CN109232748 B CN 109232748B
- Authority
- CN
- China
- Prior art keywords
- peptide
- resin
- fmoc
- hybrid peptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 282
- 108010081387 neurotensin (8-13) Proteins 0.000 title claims abstract description 40
- DQDBCHHEIKQPJD-ODKJCKIQSA-N (2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 DQDBCHHEIKQPJD-ODKJCKIQSA-N 0.000 title claims abstract description 35
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 title claims abstract description 34
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 38
- 125000004122 cyclic group Chemical group 0.000 title 1
- 238000001308 synthesis method Methods 0.000 title 1
- 239000011347 resin Substances 0.000 claims abstract description 101
- 229920005989 resin Polymers 0.000 claims abstract description 101
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 66
- 150000001413 amino acids Chemical class 0.000 claims abstract description 45
- 230000004048 modification Effects 0.000 claims abstract description 37
- 238000012986 modification Methods 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 24
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 13
- 238000009833 condensation Methods 0.000 claims abstract description 12
- 230000005494 condensation Effects 0.000 claims abstract description 12
- 239000003875 Wang resin Substances 0.000 claims abstract description 10
- 238000010189 synthetic method Methods 0.000 claims abstract description 10
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 45
- 229920001184 polypeptide Polymers 0.000 claims description 35
- 239000003153 chemical reaction reagent Substances 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 24
- NTFTULBKHJJQAW-HNNXBMFYSA-N 9h-fluoren-9-ylmethyl n-[(2s)-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C=O)C3=CC=CC=C3C2=C1 NTFTULBKHJJQAW-HNNXBMFYSA-N 0.000 claims description 23
- 239000012071 phase Substances 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000010511 deprotection reaction Methods 0.000 claims description 19
- 239000011259 mixed solution Substances 0.000 claims description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 16
- 229920005654 Sephadex Polymers 0.000 claims description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 14
- 229910052786 argon Inorganic materials 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 9
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 8
- 239000012507 Sephadex™ Substances 0.000 claims description 8
- 238000006482 condensation reaction Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- HBGPNLPABVUVKZ-POTXQNELSA-N (1r,3as,4s,5ar,5br,7r,7ar,11ar,11br,13as,13br)-4,7-dihydroxy-3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-2,3,4,5,6,7,7a,10,11,11b,12,13,13a,13b-tetradecahydro-1h-cyclopenta[a]chrysen-9-one Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1[C@H](O)C[C@]([C@]1(C)C[C@@H]3O)(C)[C@@H]2CC[C@H]1[C@@H]1[C@]3(C)CC[C@H]1C(=C)C HBGPNLPABVUVKZ-POTXQNELSA-N 0.000 claims description 7
- PFRGGOIBYLYVKM-UHFFFAOYSA-N 15alpha-hydroxylup-20(29)-en-3-one Natural products CC(=C)C1CCC2(C)CC(O)C3(C)C(CCC4C5(C)CCC(=O)C(C)(C)C5CCC34C)C12 PFRGGOIBYLYVKM-UHFFFAOYSA-N 0.000 claims description 7
- SOKRNBGSNZXYIO-UHFFFAOYSA-N Resinone Natural products CC(=C)C1CCC2(C)C(O)CC3(C)C(CCC4C5(C)CCC(=O)C(C)(C)C5CCC34C)C12 SOKRNBGSNZXYIO-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000007790 solid phase Substances 0.000 claims description 7
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- 238000004007 reversed phase HPLC Methods 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 8
- 125000006239 protecting group Chemical group 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 4
- 230000002194 synthesizing effect Effects 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 claims 1
- 238000011033 desalting Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- MQUBEBJFHBANKV-UHFFFAOYSA-N di(propan-2-yl)silicon Chemical compound CC(C)[Si]C(C)C MQUBEBJFHBANKV-UHFFFAOYSA-N 0.000 claims 1
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 28
- 230000000903 blocking effect Effects 0.000 abstract description 25
- 108010092674 Enkephalins Proteins 0.000 abstract description 24
- 229940079593 drug Drugs 0.000 abstract description 20
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 abstract description 19
- 238000010612 desalination reaction Methods 0.000 abstract description 19
- 208000004296 neuralgia Diseases 0.000 abstract description 17
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract description 16
- 101710176384 Peptide 1 Proteins 0.000 abstract description 16
- 208000021722 neuropathic pain Diseases 0.000 abstract description 15
- 230000003063 anti-neuropathic effect Effects 0.000 abstract description 13
- 229940124636 opioid drug Drugs 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 46
- 230000000202 analgesic effect Effects 0.000 description 43
- 230000036592 analgesia Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 32
- 238000002347 injection Methods 0.000 description 27
- 239000007924 injection Substances 0.000 description 27
- 229960005181 morphine Drugs 0.000 description 23
- 238000000185 intracerebroventricular administration Methods 0.000 description 17
- 150000003053 piperidines Chemical class 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 108010022337 Leucine Enkephalin Proteins 0.000 description 13
- 239000002504 physiological saline solution Substances 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 13
- -1 triazole-N, N, N', N'- tetramethylurea-hexafluorophosphate Chemical compound 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000007789 gas Substances 0.000 description 12
- 108010042237 Methionine Enkephalin Proteins 0.000 description 11
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 10
- 101800001814 Neurotensin Proteins 0.000 description 8
- 102400001103 Neurotensin Human genes 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 7
- 229930182817 methionine Natural products 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 230000007071 enzymatic hydrolysis Effects 0.000 description 6
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 6
- 238000003810 ethyl acetate extraction Methods 0.000 description 6
- 150000002469 indenes Chemical class 0.000 description 6
- 230000001376 precipitating effect Effects 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108010093625 Opioid Peptides Proteins 0.000 description 5
- 102000001490 Opioid Peptides Human genes 0.000 description 5
- 239000003399 opiate peptide Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- CPFQZWHHAOAIFM-YTTLQHOZSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-5-(diaminomethylideneamino)-2-(methylamino)pentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-methylpentanoic acid Chemical compound NC(=N)NCCC[C@H](NC)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)C(C)(C)C)CC1=CNC2=CC=CC=C12 CPFQZWHHAOAIFM-YTTLQHOZSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 229940127240 opiate Drugs 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 239000008896 Opium Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960001027 opium Drugs 0.000 description 3
- 230000008058 pain sensation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical group C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 2
- DQDBCHHEIKQPJD-IZHGMHMJSA-N 2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NC(CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 DQDBCHHEIKQPJD-IZHGMHMJSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 101800005209 Deltorphin Proteins 0.000 description 2
- BHSURCCZOBVHJJ-NWOHMYAQSA-N Deltorphin A Chemical compound C([C@H](N)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(N)=O)C1=CC=C(O)C=C1 BHSURCCZOBVHJJ-NWOHMYAQSA-N 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
- 102400000243 Leu-enkephalin Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102400000988 Met-enkephalin Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AQGDXJQRVOCUQX-UHFFFAOYSA-N N.[S] Chemical compound N.[S] AQGDXJQRVOCUQX-UHFFFAOYSA-N 0.000 description 1
- 102000017922 Neurotensin receptor Human genes 0.000 description 1
- 108060003370 Neurotensin receptor Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- HVPPEXXUDXAPOM-MGHWNKPDSA-N Tyr-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HVPPEXXUDXAPOM-MGHWNKPDSA-N 0.000 description 1
- LURVIJVAAIIEQT-RGMNGODLSA-N [S].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [S].C(CC)N[C@@H](CCO)C(=O)O LURVIJVAAIIEQT-RGMNGODLSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 108010062444 deltakephalin Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002756 mu opiate receptor agonist Substances 0.000 description 1
- 229940126487 mu opioid receptor agonist Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/70—Enkephalins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/083—Neurotensin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The cyclisation hybrid peptide that is mutually coupled with neurotensin (8-13) of enkephalins and its synthetic method of the modification of multidigit point and application are related to a kind of cyclisation hybrid peptide and its synthetic method and application.Be to solve existing opioid drug resistance to enzymolysis ability it is poor, the ineffective problem of anti-neuropathic pain.The hybrid peptide is hybrid peptide 1, hybrid peptide 2, hybrid peptide 3 or hybrid peptide 4.Method: one, the Wang resin pretreatment of " Fmoc " protection；Two, " Fmoc " blocking group is removed；Three, amino acid condensation reacts；Four, the extension of peptide chain；Five, the formation of disulfide bond；Six, peptide chain is from the cutting on resin；Seven, the desalination and purifying of thick peptide.The present invention, which replaces and be cyclized modification by multidigit point unnatural amino acid, can also enhance the biological stability of hybrid peptide, and have the function of anti-neuropathic pain.Hybrid peptide of the invention is used to prepare anti-neuropathic pain drug.
Description
Technical field
The present invention relates to a kind of cyclisation hybrid peptide and its synthetic method and applications.
Background technique
For centuries, opium and its extract are used for always analgesia therapy.The morphine isolated from opium is exactly
One of widest analgesic of present clinical application.However the defect that the drugs such as morphine are used in safety clinical is also very much, such as
Inhibit breathing, cause blood pressure reduction and areocardia, constipation, Yi Yinqi psychological dependence, habituation and analgesia tolerance etc..In addition,
Coffee is bad to the therapeutic effect of chronic ache such as neurogenic pain.It is well known that opioid peptides pain sensation information transmitting and
It plays an important role in modulated process.Early in 1974, scholars have just extracted two from pig brain had morphine sample opium
Active pentapeptide, i.e. Methionine enkephalin (Met-enkephalin) and leucine enkephalin (Leu-enkephalin), two
Person is referred to as enkephalins (enkephalins).They are to δ-opiate receptor compatibility with higher and selectivity, it is considered to be
δ-opiate receptor endogenic ligand.Two kinds of enkephalins by reduced in conjunction with its receptor in nerve cell cAMP level and calcium from
The conduction of son inhibits the neurotransmission of pain sensation regulating system, and then plays analgesic activity.Under physiological concentration, methionine brain
Deltorphin delta and leucine enkephalin are not easy to generate body psychic dependence, and drug resistance formation is slower.However enkephalins
Analgesic activities are relatively weak, hence it is evident that lower than the analgesic effect of the mediations such as μ-opioid receptor agonist such as morphine.In addition, enkephalins
Biological stability is poor, and analgesia duration is shorter, and blood-brain barrier Penetration ration is lower, to limit it as clinical antalgesic
The development of object.
American Physiological man in 1973 has found the active nerve peptide being made of 13 amino acid from ox hypothalamus, i.e., refreshing
Through hypotensor medicine (neurotensin, NT).In central nervous system, neurotensin is as neurotransmitter or quenched and play
Effect, effect include cooling, analgesia, adjust dopaminergic transmitting and the release of Stimulation of Pituitary Gland anterior lobe normone.Neurotensin exists
Inhibit have important relationship with opioid peptides in pain sensation transmittance process.Neurotensin nerve endings and neurotensin receptor exist
Be distributed widely in central nervous system with the related region of easing pain, and with endogenous opiatepeptide nerve endings and opiate receptor
It is distributed companion lines.Some researches show that the analgesic effect and activation opiate system that Central injection neurotensin generates cause endogenous
The release of property opioid peptides is related.Furthermore, it has already been proven that the 8-13 amino acids " Arg-Arg-Pro-Tyr- of neurotensin
Ile-Leu " is the active minimal segment of neurotensin, and there are two positively charged arginine in amino acid sequence.Arginine
Guanidino group can form the hydrogen bond of divalent with the anionic group of cell surface, enhancing polypeptide to the permeability of biomembrane,
Such as blood-brain barrier.
Summary of the invention
The present invention is to solve the resistance to enzymolysis ability of existing opioid drug is poor, anti-neuropathic pain is ineffective to be asked
Topic provides cyclisation hybrid peptide and its synthetic method and answer that the enkephalins that multidigit point is modified mutually is coupled with neurotensin (8-13)
With.
The enkephalins of multidigit point modification of the present invention and the cyclisation hybrid peptide that neurotensin (8-13) is mutually coupled are hybrid peptide
1, hybrid peptide 2, hybrid peptide 3 or hybrid peptide 4；
The wherein amino acid sequence of hybrid peptide 1 are as follows:
Dmt-Gly-c(Cys-NMePhe-Met-Cys)-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu；
The amino acid sequence of hybrid peptide 2 are as follows:
Dmt-Gly-c(Cys-NMePhe-Leu-Cys)-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu；
The amino acid sequence of hybrid peptide 3 are as follows:
Dmt-Gly-c(Cys-NMePhe-Met-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu；
The amino acid sequence of hybrid peptide 4 are as follows:
Dmt-Gly-c(Cys-NMePhe-Leu-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu。
Wherein sequence " Dmt-Gly-c (Cys-NMePhe-Met-Cys) " and " Dmt-Gly-c (Cys-NMePhe-Leu-
Cys) " be respectively multidigit point modification cyclisation Methionine enkephalin and leucine enkephalin residue sequence, " Gly " and
" D-Ala " is the intermediate connexon of hybrid peptide, and " NMeArg-Lys-Pro-Trp-Tle-Leu " is the nerve drop of multidigit point modification
Press the residue sequence of plain (8-13).(Dmt represents 2,6- dimethyl Tyr, and NMePhe represents N- methyl Phe, and NMeArg represents N- first
Base Arg, Tle represent tert-Leu)
The synthetic method for the cyclisation hybrid peptide that the enkephalins of above-mentioned multidigit point modification is mutually coupled with neurotensin (8-13),
The following steps are included:
One, it the Wang resin pretreatment of " Fmoc " protection: checks the air-tightness of solid phase synthetic instrument, an amino acid will be had
The Fmoc-Leu-Wang resin of residue is put into synthesizer, and add methylene chloride 30~40min of stirring, and resin is made sufficiently to impregnate swelling
Afterwards, decompression filters solvent；The wherein body of the quality of the Fmoc-Leu-Wang resin with an amino acid residue and methylene chloride
Product is than being 1g:(7~12) mL；
Two, it removes " Fmoc " blocking group: the swellable resins after draining being washed into 3~5min with DMF, are drained, repetition 3~
5 times, piperidines/DMF that concentration expressed in percentage by volume is 20%~25% is then added in resin and is deprotected solution, stirs 5~10min
After drain, repeat 2~3 times, add concentration expressed in percentage by volume be 20%~25% piperidines/DMF be deprotected solution, stirring 15~
20min removes " Fmoc " blocking group sufficiently, drains solvent later, finally washs cleared deprotection solution with DMF, obtains
Remove the resin of " Fmoc " blocking group；Wherein the quality of resin and the volume ratio for the deprotection solution being added for the first time are 1g:
(8~12) mL；The volume ratio for the deprotection solution that the quality of resin is added with second is 1g:(10~14) mL；
Three, amino acid condensation reacts: successively by the amino acid, N- hydroxy benzo triazole, O- benzene of " Fmoc " radical protection
And triazole-N, N, N', N'- tetramethylurea-hexafluorophosphate is dissolved in DMF, mixes mixed after adding diisopropylethylamine
Solution is closed, then mixed solution is added in the resin of step 2 removing " Fmoc " blocking group, is stirred under protection of argon gas
React 60~72min；
The degree that condensation reaction is completed is detected by indenes check reagent, is washed repeatedly after fully reacting with DMF to remove not instead
The residual liquid answered；
Four, the extension of peptide chain: step 2 and three is repeated, according to the sequence of heterozygosis peptide amino acid sequence, from the end C- of polypeptide
Successively the amino acid of " Fmoc " radical protection is condensed on resin one by one to the end N-, until all amino acid residues have been condensed
At obtaining peptide resin；The wherein amino acid sequence of hybrid peptide 1 are as follows: Dmt-Gly-c (Cys-NMePhe-Met-Cys)-Gly-
NMeArg-Lys-Pro-Trp-Tle-Leu；The amino acid sequence of hybrid peptide 2 are as follows: Dmt-Gly-c (Cys-NMePhe-Leu-
Cys)-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu；The amino acid sequence of hybrid peptide 3 are as follows: Dmt-Gly-c (Cys-
NMePhe-Met-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu；The amino acid sequence of hybrid peptide 4 are as follows: Dmt-
Gly-c(Cys-NMePhe-Leu-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu；
Five, the formation of disulfide bond: I is weighed2It is dissolved in anhydrous methanol and DMF mixed liquor, is made into I2Solution, and by I2Solution
It is added in peptide resin, is passed through argon gas protection, is protected from light and is stirred to react 3~5 hours cyclization, drain reaction solution；Wherein mixed solution
The volume ratio of middle anhydrous methanol and DMF are 4:1, I2Quality and mixed solution volume ratio be 2.6g:100mL, I2Solution and peptide
The volume ratio of resin is 100mL:1g；
Six, peptide chain is from the cutting on resin: " Fmoc " group of amino acid most latter linked on peptide resin is removed completely,
Then peptide resin is alternately washed with methylene chloride and methanol, after sufficiently draining solvent, cutting reagent is added into peptide resin, in room
Lower 3~the 5h of cleavage reaction of temperature；
Collect cutting reagent and depressurize and be spin-dried for, be precipitated and precipitated with ice-cold ether, remove ether supernatant after standing, then with water and
Acetic acid sufficiently dissolves precipitating, pours into separatory funnel, and ethyl acetate extraction is added, and collects water phase, freeze-dried, obtains white
The thick peptide of solid powder；
Seven, the desalination and purifying of thick peptide: using the acetic acid solution of volumetric concentration 10%-20% as mobile phase, thick peptide is passed through
Sephadex G25 cross-linked dextran gel column desalination is freeze-dried after collecting main peak using Ultraviolet Detector, obtains desalination
Polypeptide compound, then isolated and purified by Reversed Phase High Performance, main peak is collected, white is obtained after freeze-drying
The pure peptide of solid powder.
The mole of the amino acid of " Fmoc " radical protection is the 2.5- of Fmoc-Leu-Wang resin mole in step 3
3 times.
The mole of N- hydroxy benzo triazole is 2.5-3 times of Fmoc-Leu-Wang resin mole in step 3.
The mole of O- benzotriazole-N, N, N', N'- tetramethylurea-hexafluorophosphate is Fmoc-Arg in step 3
(pbf) 2.5-3 times of-Wang resin mole.
The mole of diisopropylethylamine is 5-6 times of Fmoc-Leu-Wang resin mole in step 3.
The cutting reagent of 10-25mL is added in every gram of peptide resin in step 6.
Cutting reagent described in step 6 is mixed by trifluoroacetic acid, diisopropylsilyl and water according to volume ratio 95:2.5:2.5
It closes.
" Fmoc " group of amino acid most latter linked on peptide resin is removed completely in step 6 method particularly includes:
Peptide resin is washed into 3~5min with DMF, is drained, repeats 3~5 times, concentration expressed in percentage by volume is then added in resin
It is deprotected solution for 20%~25% piperidines/DMF, is drained after stirring 5~10min, is repeated 2~3 times, add volume basis
The piperidines that concentration is 20%~25%/DMF is deprotected solution, stirs 15~20min, removes " Fmoc " blocking group sufficiently,
Solvent is drained later, is finally washed cleared deprotection solution with DMF, is removed the resin of " Fmoc " blocking group.
The cyclisation hybrid peptide that the enkephalins of above-mentioned multidigit point modification is mutually coupled with neurotensin (8-13) is preparing polypeptide
Application in analgesic.
The cyclisation hybrid peptide that the enkephalins of above-mentioned multidigit point modification is mutually coupled with neurotensin (8-13) is preparing anti-mind
Through the application in property pain medication.
Beneficial effects of the present invention:
The cyclisation hybrid peptide that the enkephalins of multidigit point modification of the present invention is mutually coupled with neurotensin (8-13), is by first sulphur
Propylhomoserin/leucine enkephalin amino acid sequence " Tyr-Gly-Gly-Phe-Met/Leu " is modified and is cyclized by multidigit point
To " Dmt-Gly-c (Cys-NMePhe-Met-Cys) " and " Dmt-Gly-c (Cys-NMePhe-Leu-Cys) " amino acid residue
Sequence modifies the amino acid sequence " Arg-Arg-Pro-Tyr-Ile-Leu " of neurotensin (8-13) by multidigit point
To " NMeArg-Lys-Pro-Trp-Tle-Leu " amino acid residue sequence, using intermediate connexon " Gly " or " D-Ala " by two
Partial amino-acid residue sequence is mutually coupled, and constructs a kind of new and effective hybrid peptide.
Wherein multidigit point modification is by methionine/leucine enkephalin amino acid sequence " Tyr-Gly-Gly-Phe-
1 Tyr of Met/Leu " is substituted with Dmt, and 3 Gly are substituted with Cys, and 4 Phe are substituted with NMePhe and 6 increase Cys.
Then it is cyclized, is specifically cyclized 3 and 6 Cys by disulfide bond.
The resistance to enzymolysis ability of polypeptide can be enhanced by the replacement of multidigit point unnatural amino acid, and be cyclized modification can also mention
The biological stability of high polypeptide drugs, various hydrolases are not easily decomposed the peptide bond of cyclized polypeptide, further enhance the anti-of polypeptide
Enzymatic hydrolysis ability, and then enhance transport capacity of the drug to cental system, improve the utilization rate and efficiency of drug.
As long as polypeptide is modified by site unnatural amino acid, then various hydrolases non-natural amino not easy to identify
Acid, not degradable polypeptide, and then enhance the resistance to enzymolysis ability of polypeptide.The modification of multidigit point, the resistance to enzymolysis ability of polypeptide is with regard to stronger.It is more
Site modification and cyclisation synergistic effect, significantly enhance the enzymatic hydrolysis stability of polypeptide.Experiment shows the small of hybrid peptide 1,2,3 and 4
Mouse brain plasma membrane half-life period respectively reach 297.1 ± 22.0min, 302.6 ± 28.7min, 447.1 ± 28.2min, 412.0 ±
The serum half-life of 31.4min, hybrid peptide 1,2,3 and 4 respectively reach 267.0 ± 20.1min, 258.5 ± 21.4min, 339.7
±21.7min、311.2±31.9min。
It is small by being added among the modification sequence of the methionine/leucine enkephalin and neurotensin (8-13) of hybrid peptide
The flexible conformation of hybrid peptide can be improved in molecule Amino acid linker " Gly " or " D-Ala ", retains methionine/leucine brain
The bioactivity of deltorphin delta and neurotensin (8-13) two parts modification sequence.Connexon " D-Ala " is because introduce D type amino
Acid will increase the resistance to enzymolysis ability of hybrid peptide.Also can moreover, modification is replaced and be cyclized by multidigit point unnatural amino acid
Enhance the biological stability of hybrid peptide.Neurotensin (8-13) is the minimum active fragment of neurotensin, the mind of hybrid peptide
Through hypotensor medicine (8-13) partially endogenic opioid peptides can be caused to discharge, analgesia is participated in and make by activating Opioid Receptor System
Performance, and then efficient analgesic activities are generated with the enkephalins part of hybrid peptide.Moreover, the hybrid peptide tool there are two band just
The amino acid of electricity, can form the hydrogen bond of divalent with the anionic group of cell surface, and enhancing hybrid peptide wears blood-brain barrier
Saturating ability, and then improve the maincenter utilization rate of drug.In addition, the neurotensin (8-13) in hybrid peptide partially can reduce Ah
The adverse side effects such as the analgesia tolerance and angiocarpy of opiates.
In addition, hybrid peptide 3 and 4 of the invention also has efficient analgesic activities to neuropathology pain.Experiment shows
The maximum analgesic effect of hybrid peptide 3 and 4 generates after injecting drug 10min, and analgesia duration is longer, it is sustainable at least
40min。
Hybrid peptide 1-4 of the invention enzymatic hydrolysis stability with higher.By central administration, hybrid peptide 1-4 is in hot whipping
All there are efficient analgesic activities in experiment.Moreover, hybrid peptide 3 and 4 has peripherally administered efficient analgesic effect, and significant
Anti- neuropathic pain activity.In addition, the medicine analgesic tolerance side effect of hybrid peptide 3 and 4 significantly reduces, especially hybrid peptide 3 has
Without analgesia tolerance characteristic, and it is significantly reduced the side effect of cardiovascular system.
Therefore, hybrid peptide of the invention is in the polypeptide analgesic for preparing efficient, low analgesia tolerance and cardiovascular side effects
Aspect has potential application and scientific meaning.
Detailed description of the invention
Fig. 1 is analgesic effect-time graph of intracerebroventricular injection hybrid peptide 1；Wherein ■ indicates hybrid peptide 1,10nmol, ●
Indicate hybrid peptide 1,3nmol, ▲ indicate that hybrid peptide 1,1nmol, ▼ indicate hybrid peptide 1,0.3nmol, ◆ indicate physiological saline；
Fig. 2 is analgesic effect-time graph of intracerebroventricular injection hybrid peptide 2；Wherein ■ indicates hybrid peptide 2,10nmol, ●
Indicate hybrid peptide 2,3nmol, ▲ indicate that hybrid peptide 2,1nmol, ▼ indicate hybrid peptide 2,0.3nmol, ◆ indicate physiological saline；
Fig. 3 is analgesic effect-time graph of intracerebroventricular injection hybrid peptide 3；Wherein ■ indicates hybrid peptide 3,10nmol, ●
Indicate hybrid peptide 3,3nmol, ▲ indicate that hybrid peptide 3,1nmol, ▼ indicate hybrid peptide 3,0.3nmol, ◆ indicate physiological saline；
Fig. 4 is analgesic effect-time graph of intracerebroventricular injection hybrid peptide 4；Wherein ■ indicates hybrid peptide 4,10nmol, ●
Indicate hybrid peptide 4,3nmol, ▲ indicate that hybrid peptide 4,1nmol, ▼ indicate hybrid peptide 4,0.3nmol, ◆ indicate physiological saline；
Fig. 5 is the periphery analgesic effect that hybrid peptide 3 and 4 is subcutaneously injected；Wherein ■ indicates hybrid peptide 3 (10 μm of ol/kg, skin
Under), ● indicate hybrid peptide 4 (10 μm of ol/kg, subcutaneous), ▲ indicate physiological saline (subcutaneous)；
Fig. 6 is the analgesia tolerance dose curve of intracerebroventricular injection morphine；Wherein ■ indicates physiological saline+morphine, ● it indicates
Morphine (10nmol)+morphine；
Fig. 7 is the analgesia tolerance dose curve of intracerebroventricular injection hybrid peptide 3；Wherein ■ indicates physiological saline+hybrid peptide 3,
● indicate hybrid peptide 3 (10nmol)+hybrid peptide 3；
Fig. 8 is the analgesia tolerance dose curve of intracerebroventricular injection hybrid peptide 4；Wherein ■ indicates physiological saline+hybrid peptide 4,
● indicate hybrid peptide 4 (10nmol)+hybrid peptide 4；
Fig. 9 is the anti-neuropathic pain activity of intracerebroventricular injection hybrid peptide 3；Wherein ■ indicates hybrid peptide 3,10nmol, ●
Indicate hybrid peptide 3,3nmol, ▲ indicate that hybrid peptide 3,1nmol, ▼ indicate physiological saline；
Figure 10 is the anti-neuropathic pain activity of intracerebroventricular injection hybrid peptide 4；Wherein ■ indicates hybrid peptide 4,10nmol, ●
Indicate hybrid peptide 4,3nmol, ▲ indicate that hybrid peptide 4,1nmol, ▼ indicate physiological saline；
Figure 11 is the effect of intravenous morphine and hybrid peptide 3 and 4 pair rat system angiosthenia；
Figure 12 is the effect of intravenous morphine and hybrid peptide 3 and 4 pair rat heart rate.
Specific embodiment
The technical solution of the present invention is not limited to the following list, further includes between each specific embodiment
Any combination.
Specific embodiment 1: what the enkephalins of present embodiment multidigit point modification was mutually coupled with neurotensin (8-13)
Cyclisation hybrid peptide is hybrid peptide 1, hybrid peptide 2, hybrid peptide 3 or hybrid peptide 4；
The wherein amino acid sequence of hybrid peptide 1 are as follows:
Dmt-Gly-c(Cys-NMePhe-Met-Cys)-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu；
The amino acid sequence of hybrid peptide 2 are as follows:
Dmt-Gly-c(Cys-NMePhe-Leu-Cys)-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu；
The amino acid sequence of hybrid peptide 3 are as follows:
Dmt-Gly-c(Cys-NMePhe-Met-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu；
The amino acid sequence of hybrid peptide 4 are as follows:
Dmt-Gly-c(Cys-NMePhe-Leu-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu。
Present embodiment is by methionine/leucine enkephalin amino acid sequence " Tyr-Gly-Gly-Phe-Met/
Leu " obtains " Dmt-Gly-c (Cys-NMePhe-Met-Cys) " and " Dmt-Gly-c (Cys- with cyclisation by the modification of multidigit point
NMePhe-Leu-Cys) " amino acid residue sequence, by the amino acid sequence " Arg-Arg-Pro- of neurotensin (8-13)
Tyr-Ile-Leu " modifies to obtain " NMeArg-Lys-Pro-Trp-Tle-Leu " amino acid residue sequence by multidigit point, utilizes
Two parts amino acid residue sequence is mutually coupled by intermediate connexon " Gly " or " D-Ala ", constructs a kind of efficient hybrid peptide.
The resistance to enzymolysis ability of polypeptide can be enhanced by the replacement of multidigit point unnatural amino acid, and be cyclized modification can also mention
The biological stability of high polypeptide drugs, various hydrolases are not easily decomposed the peptide bond of cyclized polypeptide, further enhance the anti-of polypeptide
Enzymatic hydrolysis ability, and then enhance transport capacity of the drug to cental system, improve the utilization rate and efficiency of drug.
Specific embodiment 2: what the enkephalins of present embodiment multidigit point modification was mutually coupled with neurotensin (8-13)
It is cyclized the synthetic method of hybrid peptide, comprising the following steps:
One, it the Wang resin pretreatment of " Fmoc " protection: checks the air-tightness of solid phase synthetic instrument, an amino acid will be had
The Fmoc-Leu-Wang resin of residue is put into synthesizer, and add methylene chloride 30~40min of stirring, and resin is made sufficiently to impregnate swelling
Afterwards, decompression filters solvent；The wherein body of the quality of the Fmoc-Leu-Wang resin with an amino acid residue and methylene chloride
Product is than being 1g:(7~12) mL；
Two, it removes " Fmoc " blocking group: the swellable resins after draining being washed into 3~5min with DMF, are drained, repetition 3~
5 times, piperidines/DMF that concentration expressed in percentage by volume is 20%~25% is then added in resin and is deprotected solution, stirs 5~10min
After drain, repeat 2~3 times, add concentration expressed in percentage by volume be 20%~25% piperidines/DMF be deprotected solution, stirring 15~
20min removes " Fmoc " blocking group sufficiently, drains solvent later, finally washs cleared deprotection solution with DMF, obtains
Remove the resin of " Fmoc " blocking group；Wherein the quality of resin and the volume ratio for the deprotection solution being added for the first time are 1g:
(8~12) mL；The volume ratio for the deprotection solution that the quality of resin is added with second is 1g:(10~14) mL；
Three, amino acid condensation reacts: successively by the amino acid, N- hydroxy benzo triazole, O- benzene of " Fmoc " radical protection
And triazole-N, N, N', N'- tetramethylurea-hexafluorophosphate is dissolved in DMF, mixes mixed after adding diisopropylethylamine
Solution is closed, then mixed solution is added in the resin of step 2 removing " Fmoc " blocking group, is stirred under protection of argon gas
React 60~72min；
The degree that condensation reaction is completed is detected by indenes check reagent, is washed repeatedly after fully reacting with DMF to remove not instead
The residual liquid answered；
Four, the extension of peptide chain: step 2 and three is repeated, according to the sequence of heterozygosis peptide amino acid sequence, from the end C- of polypeptide
Successively the amino acid of " Fmoc " radical protection is condensed on resin one by one to the end N-, until all amino acid residues have been condensed
At obtaining peptide resin；The wherein amino acid sequence of hybrid peptide 1 are as follows: Dmt-Gly-c (Cys-NMePhe-Met-Cys)-Gly-
NMeArg-Lys-Pro-Trp-Tle-Leu；The amino acid sequence of hybrid peptide 2 are as follows: Dmt-Gly-c (Cys-NMePhe-Leu-
Cys)-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu；The amino acid sequence of hybrid peptide 3 are as follows: Dmt-Gly-c (Cys-
NMePhe-Met-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu；The amino acid sequence of hybrid peptide 4 are as follows: Dmt-
Gly-c(Cys-NMePhe-Leu-Cys)-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu；
Five, the formation of disulfide bond: I is weighed2It is dissolved in anhydrous methanol and DMF mixed liquor, is made into I2Solution, and by I2Solution
It is added in peptide resin, is passed through argon gas protection, is protected from light and is stirred to react 3~5 hours cyclization, drain reaction solution；Wherein mixed solution
The volume ratio of middle anhydrous methanol and DMF are 4:1, I2Quality and mixed solution volume ratio be 2.6g:100mL, I2Solution and peptide
The volume ratio of resin is 100mL:1g；
Six, peptide chain is from the cutting on resin: " Fmoc " group of amino acid most latter linked on peptide resin is removed completely,
Then peptide resin is alternately washed with methylene chloride and methanol, after sufficiently draining solvent, cutting reagent is added into peptide resin, in room
Lower 3~the 5h of cleavage reaction of temperature；
Collect cutting reagent and depressurize and be spin-dried for, be precipitated and precipitated with ice-cold ether, remove ether supernatant after standing, then with water and
Acetic acid sufficiently dissolves precipitating, pours into separatory funnel, and ethyl acetate extraction is added, and collects water phase, freeze-dried, obtains white
The thick peptide of solid powder；
Seven, the desalination and purifying of thick peptide: using the acetic acid solution of volumetric concentration 10%-20% as mobile phase, thick peptide is passed through
Sephadex G25 cross-linked dextran gel column desalination is freeze-dried after collecting main peak using Ultraviolet Detector, obtains desalination
Polypeptide compound, then isolated and purified by Reversed Phase High Performance, main peak is collected, white is obtained after freeze-drying
The pure peptide of solid powder.
Specific embodiment 3: present embodiment is unlike specific embodiment two: " Fmoc " group in step 3
The mole of the amino acid of protection is 2.5-3 times of Fmoc-Leu-Wang resin mole.Other and specific embodiment two-phase
Together.
Specific embodiment 4: present embodiment is unlike specific embodiment two or three: N- hydroxyl in step 3
The mole of benzotriazole is 2.5-3 times of Fmoc-Leu-Wang resin mole.Other and specific embodiment two or three
It is identical.
Specific embodiment 5: unlike one of present embodiment and specific embodiment two to four: O- in step 3
The mole of benzotriazole-N, N, N', N'- tetramethylurea-hexafluorophosphate is Fmoc-Arg (pbf)-Wang resin mole
2.5-3 times of amount.It is other identical as one of specific embodiment two to four.
Specific embodiment 6: unlike one of present embodiment and specific embodiment two to five: two in step 3
The mole of wopropyl ethyl amine is 5-6 times of Fmoc-Leu-Wang resin mole.It is other with specific embodiment two to five it
One is identical.
Specific embodiment 7: unlike one of present embodiment and specific embodiment two to six: every in step 6
The cutting reagent of 10-25mL is added in gram peptide resin.It is other identical as one of specific embodiment two to six.
Specific embodiment 8: present embodiment is unlike specific embodiment seven: cutting examination described in step 6
Agent is mixed by trifluoroacetic acid, diisopropylsilyl and water according to volume ratio 95:2.5:2.5.Other and specific embodiment
Seven is identical.
Specific embodiment 9: unlike one of present embodiment and specific embodiment two to eight: will in step 6
" Fmoc " group of most latter linked amino acid removes completely on peptide resin method particularly includes:
Peptide resin is washed into 3~5min with DMF, is drained, repeats 3~5 times, concentration expressed in percentage by volume is then added in resin
It is deprotected solution for 20%~25% piperidines/DMF, is drained after stirring 5~10min, is repeated 2~3 times, add volume basis
The piperidines that concentration is 20%~25%/DMF is deprotected solution, stirs 15~20min, removes " Fmoc " blocking group sufficiently,
Solvent is drained later, is finally washed cleared deprotection solution with DMF, is removed the resin of " Fmoc " blocking group.It is other with
One of specific embodiment two to eight is identical.
Specific embodiment 10: what the enkephalins of present embodiment multidigit point modification was mutually coupled with neurotensin (8-13)
Cyclisation hybrid peptide is preparing the application in polypeptide analgesic.
Specific embodiment 11: the enkephalins of present embodiment multidigit point modification is mutually coupled with neurotensin (8-13)
Cyclisation hybrid peptide preparing the application in anti-neuropathic pain drug.
Elaborate below to the embodiment of the present invention, following embodiment under the premise of the technical scheme of the present invention into
Row is implemented, and gives detailed embodiment and specific operating process, but protection scope of the present invention is not limited to following realities
Apply example.
Embodiment 1:
The synthesis for the cyclisation hybrid peptide 1 that the enkephalins of the present embodiment multidigit point modification is mutually coupled with neurotensin (8-13)
Method, comprising the following steps:
One, it the Wang resin pretreatment of " Fmoc " protection: checks the air-tightness of solid phase synthetic instrument, 1g is had into an amino
The Fmoc-Leu-Wang resin of sour residue is put into synthesizer, adds 10mL methylene chloride to stir 30min, impregnates resin sufficiently molten
After swollen, decompression filters solvent.
Two, it removes " Fmoc " blocking group: the swellable resins after draining being washed into 3min with DMF, drains, is repeated 3 times.?
Piperidines/DMF that 10mL concentration expressed in percentage by volume is 20% is added in resin and is deprotected solution, drains, is repeated 2 times after stirring 5min,
It adds piperidines/DMF that 12mL concentration expressed in percentage by volume is 20% and is deprotected solution, stir 15min, fill " Fmoc " blocking group
Divide removing, drains solvent later, finally wash cleared deprotecting regent with 10mL DMF, removed " Fmoc " blocking group
Resin.
Three, amino acid condensation reacts: successively will be equivalent to " Fmoc " of 2.5-3 times of mole of Fmoc-Leu-Wang resin
Amino acid, N- hydroxy benzo triazole, O- benzotriazole-N, N, N', the N'- tetramethylurea-hexafluorophosphate of radical protection
It is dissolved in 10mL DMF, is mixed after adding the diisopropylethylamine for being equivalent to 5-6 times of mole of Fmoc-Leu-Wang resin
Then mixed solution is added in the resin of the deprotection, is stirred to react 60min under protection of argon gas by mixed solution.
The degree that condensation reaction is completed is detected by indenes check reagent, is washed repeatedly after fully reacting with DMF to remove unreacted residual
Liquid.
Four, the extension of peptide chain: step 2 and three is repeated, according to the sequence Dmt-Gly-Cys- of 1 amino acid sequence of hybrid peptide
NMePhe-Met-Cys-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu, from the end C- of polypeptide to the end N- successively by " Fmoc "
The amino acid of radical protection is condensed on resin one by one, until the condensation of all amino acid residues is completed, obtains peptide resin.
Five, the formation of disulfide bond: the I of 2.6g is weighed2It is dissolved in the DMF mixed liquor of 80mL anhydrous methanol and 20mL, is made into
The I of 0.1mol/L2Solution, and add it in peptide resin, it is passed through argon gas protection, is protected from light and is stirred to react 3~5 hours cyclization,
Drain reaction solution.
Six, peptide chain is from the cutting on resin: according to the method for step 2 by amino acid most latter linked on peptide resin
" Fmoc " group removes completely.Resin is alternately washed with methylene chloride, methanol, after sufficiently draining solvent, is added by every gram of peptide resin
Enter the cutting reagent of 18mL, cutting reagent by trifluoroacetic acid, diisopropylsilyl, water with the volume ratio mixing of 95:2.5:2.5 and
At cleavage reaction 3h at room temperature.It collects cutting reagent and depressurizes and be spin-dried for, be precipitated and precipitated with ice-cold ether, standing is gone in a moment
Precipitating is sufficiently dissolved except ether supernatant, then with water and a small amount of acetic acid, pours into separatory funnel, and ethyl acetate extraction is added, is collected
Water phase, it is freeze-dried, obtain the thick peptide of white solid powder.
Seven, the desalination and purifying of thick peptide: using the acetic acid solution of volumetric concentration 16% as mobile phase, thick peptide is passed through
Sephadex G25 cross-linked dextran gel column desalination is freeze-dried after collecting main peak using Ultraviolet Detector, obtains desalination
Polypeptide compound.It is isolated and purified again by Reversed Phase High Performance, collects main peak, white is obtained after freeze-drying
Solid end product hybrid peptide 1.
Embodiment 2:
The synthesis for the cyclisation hybrid peptide 1 that the enkephalins of the present embodiment multidigit point modification is mutually coupled with neurotensin (8-13)
Method, comprising the following steps:
One, it the Wang resin pretreatment of " Fmoc " protection: checks the air-tightness of solid phase synthetic instrument, 1g is had into an amino
The Fmoc-Leu-Wang resin of sour residue is put into synthesizer, adds 10mL methylene chloride to stir 30min, impregnates resin sufficiently molten
After swollen, decompression filters solvent.
Two, it removes " Fmoc " blocking group: the swellable resins after draining being washed into 3min with DMF, drains, is repeated 3 times.?
Piperidines/DMF that 10mL concentration expressed in percentage by volume is 20% is added in resin and is deprotected solution, drains, is repeated 2 times after stirring 5min,
It adds piperidines/DMF that 12mL concentration expressed in percentage by volume is 20% and is deprotected solution, stir 15min, fill " Fmoc " blocking group
Divide removing, drains solvent later, finally wash cleared deprotecting regent with 10mL DMF, removed " Fmoc " blocking group
Resin.
Three, amino acid condensation reacts: successively will be equivalent to " Fmoc " of 2.5-3 times of mole of Fmoc-Leu-Wang resin
Amino acid, N- hydroxy benzo triazole, O- benzotriazole-N, N, N', the N'- tetramethylurea-hexafluorophosphate of radical protection
It is dissolved in 10mL DMF, is mixed after adding the diisopropylethylamine for being equivalent to 5-6 times of mole of Fmoc-Leu-Wang resin
Then mixed solution is added in the resin of the deprotection, is stirred to react 60min under protection of argon gas by mixed solution.
The degree that condensation reaction is completed is detected by indenes check reagent, is washed repeatedly after fully reacting with DMF to remove unreacted residual
Liquid.
Four, the extension of peptide chain: step 2 and three is repeated, according to the sequence Dmt-Gly-Cys- of 1 amino acid sequence of hybrid peptide
NMePhe-Leu-Cys-Gly-NMeArg-Lys-Pro-Trp-Tle-Leu, from the end C- of polypeptide to the end N- successively by " Fmoc "
The amino acid of radical protection is condensed on resin one by one, until the condensation of all amino acid residues is completed, obtains peptide resin.
Five, the formation of disulfide bond: the I of 2.6g is weighed2It is dissolved in the DMF mixed liquor of 80mL anhydrous methanol and 20mL, is made into
The I of 0.1mol/L2Solution, and add it in peptide resin, it is passed through argon gas protection, is protected from light and is stirred to react 3~5 hours cyclization,
Drain reaction solution.
Six, peptide chain is from the cutting on resin: according to the method for step 2 by amino acid most latter linked on peptide resin
" Fmoc " group removes completely.Resin is alternately washed with methylene chloride, methanol, after sufficiently draining solvent, is added by every gram of peptide resin
Enter the cutting reagent of 18mL, cutting reagent by trifluoroacetic acid, diisopropylsilyl, water with the volume ratio mixing of 95:2.5:2.5 and
At cleavage reaction 3h at room temperature.It collects cutting reagent and depressurizes and be spin-dried for, be precipitated and precipitated with ice-cold ether, standing is gone in a moment
Precipitating is sufficiently dissolved except ether supernatant, then with water and a small amount of acetic acid, pours into separatory funnel, and ethyl acetate extraction is added, is collected
Water phase, it is freeze-dried, obtain the thick peptide of white solid powder.
Seven, the desalination and purifying of thick peptide: using the acetic acid solution of volumetric concentration 16% as mobile phase, thick peptide is passed through
Sephadex G25 cross-linked dextran gel column desalination is freeze-dried after collecting main peak using Ultraviolet Detector, obtains desalination
Polypeptide compound.It is isolated and purified again by Reversed Phase High Performance, collects main peak, white is obtained after freeze-drying
Solid end product hybrid peptide 2.
Embodiment 3:
The synthesis for the cyclisation hybrid peptide 1 that the enkephalins of the present embodiment multidigit point modification is mutually coupled with neurotensin (8-13)
Method, comprising the following steps:
One, it the Wang resin pretreatment of " Fmoc " protection: checks the air-tightness of solid phase synthetic instrument, 1g is had into an amino
The Fmoc-Leu-Wang resin of sour residue is put into synthesizer, adds 10mL methylene chloride to stir 30min, impregnates resin sufficiently molten
After swollen, decompression filters solvent.
Two, it removes " Fmoc " blocking group: the swellable resins after draining being washed into 3min with DMF, drains, is repeated 3 times.?
Piperidines/DMF that 10mL concentration expressed in percentage by volume is 20% is added in resin and is deprotected solution, drains, is repeated 2 times after stirring 5min,
It adds piperidines/DMF that 12mL concentration expressed in percentage by volume is 20% and is deprotected solution, stir 15min, fill " Fmoc " blocking group
Divide removing, drains solvent later, finally wash cleared deprotecting regent with 10mL DMF, removed " Fmoc " blocking group
Resin.
Three, amino acid condensation reacts: successively will be equivalent to " Fmoc " of 2.5-3 times of mole of Fmoc-Leu-Wang resin
Amino acid, N- hydroxy benzo triazole, O- benzotriazole-N, N, N', the N'- tetramethylurea-hexafluorophosphate of radical protection
It is dissolved in 10mL DMF, is mixed after adding the diisopropylethylamine for being equivalent to 5-6 times of mole of Fmoc-Leu-Wang resin
Then mixed solution is added in the resin of the deprotection, is stirred to react 60min under protection of argon gas by mixed solution.
The degree that condensation reaction is completed is detected by indenes check reagent, is washed repeatedly after fully reacting with DMF to remove unreacted residual
Liquid.
Four, the extension of peptide chain: step 2 and three is repeated, according to the sequence Dmt-Gly-Cys- of 1 amino acid sequence of hybrid peptide
NMePhe-Met-Cys-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu successively will from the end C- of polypeptide to the end N-
The amino acid of " Fmoc " radical protection is condensed on resin one by one, until the condensation of all amino acid residues is completed, obtains peptide resin.
Five, the formation of disulfide bond: the I of 2.6g is weighed2It is dissolved in the DMF mixed liquor of 80mL anhydrous methanol and 20mL, is made into
The I of 0.1mol/L2Solution, and add it in peptide resin, it is passed through argon gas protection, is protected from light and is stirred to react 3~5 hours cyclization,
Drain reaction solution.
Six, peptide chain is from the cutting on resin: according to the method for step 2 by amino acid most latter linked on peptide resin
" Fmoc " group removes completely.Resin is alternately washed with methylene chloride, methanol, after sufficiently draining solvent, is added by every gram of peptide resin
Enter the cutting reagent of 18mL, cutting reagent by trifluoroacetic acid, diisopropylsilyl, water with the volume ratio mixing of 95:2.5:2.5 and
At cleavage reaction 3h at room temperature.It collects cutting reagent and depressurizes and be spin-dried for, be precipitated and precipitated with ice-cold ether, standing is gone in a moment
Precipitating is sufficiently dissolved except ether supernatant, then with water and a small amount of acetic acid, pours into separatory funnel, and ethyl acetate extraction is added, is collected
Water phase, it is freeze-dried, obtain the thick peptide of white solid powder.
Seven, the desalination and purifying of thick peptide: using the acetic acid solution of volumetric concentration 16% as mobile phase, thick peptide is passed through
Sephadex G25 cross-linked dextran gel column desalination is freeze-dried after collecting main peak using Ultraviolet Detector, obtains desalination
Polypeptide compound.It is isolated and purified again by Reversed Phase High Performance, collects main peak, white is obtained after freeze-drying
Solid end product hybrid peptide 3.
Embodiment 4:
The synthesis for the cyclisation hybrid peptide 1 that the enkephalins of the present embodiment multidigit point modification is mutually coupled with neurotensin (8-13)
Method, comprising the following steps:
One, it the Wang resin pretreatment of " Fmoc " protection: checks the air-tightness of solid phase synthetic instrument, 1g is had into an amino
The Fmoc-Leu-Wang resin of sour residue is put into synthesizer, adds 10mL methylene chloride to stir 30min, impregnates resin sufficiently molten
After swollen, decompression filters solvent.
Two, it removes " Fmoc " blocking group: the swellable resins after draining being washed into 3min with DMF, drains, is repeated 3 times.?
Piperidines/DMF that 10mL concentration expressed in percentage by volume is 20% is added in resin and is deprotected solution, drains, is repeated 2 times after stirring 5min,
It adds piperidines/DMF that 12mL concentration expressed in percentage by volume is 20% and is deprotected solution, stir 15min, fill " Fmoc " blocking group
Divide removing, drains solvent later, finally wash cleared deprotecting regent with 10mL DMF, removed " Fmoc " blocking group
Resin.
Three, amino acid condensation reacts: successively will be equivalent to " Fmoc " of 2.5-3 times of mole of Fmoc-Leu-Wang resin
Amino acid, N- hydroxy benzo triazole, O- benzotriazole-N, N, N', the N'- tetramethylurea-hexafluorophosphate of radical protection
It is dissolved in 10mL DMF, is mixed after adding the diisopropylethylamine for being equivalent to 5-6 times of mole of Fmoc-Leu-Wang resin
Then mixed solution is added in the resin of the deprotection, is stirred to react 60min under protection of argon gas by mixed solution.
The degree that condensation reaction is completed is detected by indenes check reagent, is washed repeatedly after fully reacting with DMF to remove unreacted residual
Liquid.
Four, the extension of peptide chain: step 2 and three is repeated, according to the sequence Dmt-Gly-Cys- of 1 amino acid sequence of hybrid peptide
NMePhe-Leu-Cys-D-Ala-NMeArg-Lys-Pro-Trp-Tle-Leu successively will from the end C- of polypeptide to the end N-
The amino acid of " Fmoc " radical protection is condensed on resin one by one, until the condensation of all amino acid residues is completed, obtains peptide resin.
Five, the formation of disulfide bond: the I of 2.6g is weighed2It is dissolved in the DMF mixed liquor of 85mL anhydrous methanol and 10mL, is made into
The I of 0.1mol/L2Solution, and add it in peptide resin, it is passed through argon gas protection, is protected from light and is stirred to react 3~5 hours cyclization,
Drain reaction solution.
Six, peptide chain is from the cutting on resin: according to the method for step 2 by amino acid most latter linked on peptide resin
" Fmoc " group removes completely.Resin is alternately washed with methylene chloride, methanol, after sufficiently draining solvent, is added by every gram of peptide resin
Enter the cutting reagent of 18mL, cutting reagent by trifluoroacetic acid, diisopropylsilyl, water with the volume ratio mixing of 95:2.5:2.5 and
At cleavage reaction 3h at room temperature.It collects cutting reagent and depressurizes and be spin-dried for, be precipitated and precipitated with ice-cold ether, standing is gone in a moment
Precipitating is sufficiently dissolved except ether supernatant, then with water and a small amount of acetic acid, pours into separatory funnel, and ethyl acetate extraction is added, is collected
Water phase, it is freeze-dried, obtain the thick peptide of white solid powder.
Seven, the desalination and purifying of thick peptide: using the acetic acid solution of volumetric concentration 16% as mobile phase, thick peptide is passed through
Sephadex G25 cross-linked dextran gel column desalination is freeze-dried after collecting main peak using Ultraviolet Detector, obtains desalination
Polypeptide compound.It is isolated and purified again by Reversed Phase High Performance, collects main peak, white is obtained after freeze-drying
Solid end product hybrid peptide 4.
The ultimate yield of the hybrid peptide of above embodiments preparation reaches 25% or more, mass spectrum and chromatography testing result
As shown in table 1.
The mass spectrum and chromatography testing result of 1. hybrid peptide 1-4 of table
Table 1 the result shows that, the detected value for the hybrid peptide 1-4 that the present invention obtains is consistent with theoretical value.
The cyclisation heterozygosis that the enkephalins of the multidigit point modification of the present embodiment 1-4 preparation is mutually coupled with neurotensin (8-13)
The biological activity test of peptide is as follows:
1, unorganized ferment Numerical solution is tested
100% mice serum and 15% brain membrane sample are prepared, 10 μ L polypeptide mother liquors (10 are taken-2M), it is added to 190 μ L's
In 100% mice serum or 15% brain plasma membrane, oscillation is mixed immediately, then takes out 20 μ L mixed liquors rapidly, is added in centrifuge tube
Timing is 0min, and remaining person continues to be incubated at 37 DEG C, and respectively in 5min, 10min, 15min, 30min, 60min, 120min,
240min takes out 20 μ L.The termination of enzymolysis process: the oscillation of 90 μ L acetonitriles is added in the sample of taking-up and mixes, sample is placed on ice
5min is placed, then with the ice-cold acetic acid dilution of 90 μ L 0.5% to ensure that enzymolysis process stops.13,000g centrifugation 15min, are collected
Supernatant, -80 DEG C freeze, until RP-HPLC is analyzed.
Experimental result is shown in Table 2.Table 2 the results show that the mouse brain plasma membrane long half time of hybrid peptide 1 in serum half-life,
The mouse brain plasma membrane and serum half-life and hybrid peptide 1 of hybrid peptide 2 are suitable.And the brain plasma membrane and serum half-life of hybrid peptide 3 and 4
It is all considerably longer than hybrid peptide 1 and 2, shows space connexon " D-Ala " because introducing D type amino acid, enhances hybrid peptide
Resistance to enzymolysis ability.Wherein, half-life period longest of the hybrid peptide 3 in two kinds of samples, i.e. enzymatic hydrolysis stability highest.It should be the result shows that logical
Excessive site unnatural amino acid modification, the introducing and polypeptide cyclisation of space connexon " D-Ala " can significantly improve heterozygosis
The enzymatic hydrolysis stability of peptide 3 and 4.
The brain plasma membrane and serum half-life of 2. hybrid peptide 1-4 of table
2, hot whipping analgesic experiment
It tests and uses Kunming system male mice, 18-22g, environment temperature: 20 DEG C, bath temperature: 50 ± 0.5 DEG C.Before administration
The 1/3-1/2 of mouse rat-tail is immersed water-bath, records rat-tail by the Basic Pain Threshold (control latency, CL) for first measuring mouse
Water-bath is immersed to the time shunk from rigid.Too sensitive (<3s) or blunt (>5s) mouse is discarded, deadline
10s, to prevent mouse from scalding.It is latent respectively to survey a whipping by 5,10,15,20,25,30,40and 50min after telocoele administration
Phase (test latency, TL), the 5th, 10,15,20,25,30,45,60and 90min respectively surveys a TL after subcutaneous administration,
0.9% physiological saline is as blank control.As a result with maximum possible effect percentage (maximum possible effect, %
MPE it) indicates: %MPE=100 × (TL-CL)/(10-CL).
The hot whipping analgesic experiment result of the mouse of central administration is as shown in Fig. 1,2,3 and 4, intracerebroventricular injection 0.3-10nmol
The hybrid peptide 1-4 of dosage all has significant analgesic activities, and is in concentration-dependant, and maximum analgesic effect is in injection drug
It is generated after 10min.Wherein, the hybrid peptide 3 and 4 of Central injection 10nmol high dose, maximum analgesia %MPE value are respectively
92.46% and 87.91%.In addition, hybrid peptide 1-4 have longer analgesia duration, sustainable at least 50min or more, this
Show that hybrid peptide has efficient central analgesia activity.In addition, peripherally administered analgesic experiment result is as shown in figure 5, pass through skin
The hybrid peptide 3 and 4 of 10 μm of ol/kg dosage of lower injection, as a result, it has been found that hybrid peptide 3 and 4 still has efficient analgesic activities.Heterozygosis
The maximum analgesic effect of peptide 3 and 4 generates after injecting drug 15min, and maximum analgesia %MPE value is respectively 85.16% He
81.78%.The analgesia %MPE value that 90min measures hybrid peptide 3 and 4 upon administration remains to reach 31.68% and 28.26%, shows
The analgesia duration of peripheral injection hybrid peptide 3 and 4 can reach 90min or more, i.e., the analgesia duration of hybrid peptide 3 and 4 compared with
It is long.The novel cyclized hybrid peptide that the above results show that enkephalins and the neurotensin (8-13) of multidigit point modification are mutually coupled is significant
Analgesic activities and the duration of drug are enhanced, has the characteristics of efficient analgesic activities.
3, Acute brain block is tested
Kunming system male mice, 18-22g, environment temperature: 20 DEG C are chosen in experiment.It is intubated using PE-10 to mouse telocoele
Pipe laying is administered for 3 days after operation.According to the analgesic activities of hybrid peptide, drug dose is determined, measure acute analgesia tolerance.Mouse mentions
Preceding 1 hour intracerebroventricular injection drug or physiological saline 1 time, inject the drug of various dose respectively later, and measurement pain threshold becomes
Change, and then analgesia tolerance assessment is carried out to hybrid peptide, by morphine as positive control.
Central injection morphine, hybrid peptide 3 and 4 analgesia tolerance result as shown in Fig. 6,7 and 8,1 hour in advance to mouse side
Intracerebroventricular physiological saline, the morphine, hybrid peptide 3 and 4 of intracerebroventricular injection 0.3-10nmol various dose generates obviously later
Analgesic effect, and be in concentration-dependant feature, show that shifting to an earlier date injecting normal saline to mouse has no effect on morphine, hybrid peptide 3
With the activity of 4 equal analgesics.However, being injected again later by the morphine for shifting to an earlier date 1 hour intracerebroventricular injection 10nmol dosage
The corresponding drug morphine of 0.3-10nmol various dose, medicine analgesic dose curve obviously move to right, and central analgesia activity is aobvious
Writing reduces, i.e., morphine produces apparent medicine analgesic tolerance.But 1 hour in advance intracerebroventricular injection 10nmol dosage is miscellaneous
Peptide 3 is closed, then injects the hybrid peptide 3 of 0.3-10nmol various dose, the town of analgesic dose curve and injecting normal saline in advance
Pain dose curve is almost overlapped, and there is no generate significantly to move to left or move to right.It should be the result shows that injection hybrid peptide 3 be to the in advance
The analgesic activities of secondary acute injection hybrid peptide 3 have little effect, and show that hybrid peptide 3 has the analgesia without tolerance side effect special
Property.In addition, the hybrid peptide 4 of 1 hour in advance intracerebroventricular injection 10nmol dosage, then inject the heterozygosis of 0.3-10nmol various dose
Peptide 4, medicine analgesic dose curve move to right that degree is smaller compared with morphine, show that the analgesia tolerance of hybrid peptide 4 is substantially reduced.
The above result shows that the medicine analgesic tolerance side effect of hybrid peptide 3 and 4 significantly reduces, especially hybrid peptide 3 has the height without tolerance
Imitate analgesic properties.
4, anti-neuropathic pain experiment
Animal models of neuropathic pain is established by the method stabilization that mouse sciatic nerve branching selection damages.Experiment
Selection Kunming system male mice, 20-25g, wherein two for tightly pricking and cutting off three branch of sciatic nerve end of mouse side, i.e.,
Nervus tibialis and nervus peroneus communis branch retain nervus suralis branch.The postoperative 24 hours pain for starting duration occur, duration
Up to 7 weeks or more, i.e., induction of stable neuropathic pain animal model.The mechanical threshold of pain, research are measured by Von Frey fiber
The anti-neuropathic pain activity of Central injection drug.
The anti-neuropathic pain exercising result of Central injection hybrid peptide 3 and 4 is as shown in Figures 9 and 10, intracerebroventricular injection 1-
The hybrid peptide 3 and 4 of 10nmol is dose-dependent to cause the paw withdrawal threshold of reaction to increase, it was demonstrated that hybrid peptide 3 and 4 has apparent anti-mind
Through property pain activity.The maximum analgesic effect of hybrid peptide 3 and 4 generates after injecting drug 10min, and analgesia duration compared with
Long, sustainable at least 40min shows that hybrid peptide 3 and 4 pair neuropathology pain has efficient analgesic activities.
5, rat in vivo Blood Pressure Experiment
Using Wistar rat, 200-300g, with 20% Anaesthesia with Ethyl Carbamate (l.2g/kg, i.p.), in order to protect
It is good to hold narcosis, it may be necessary to temporarily add anaesthetic.The tracheae of incision rat, removes mucus in managing, and animal can be certainly
Main breathing.PE-50 conduit is inserted into vena jugularis externa in case intravenously administrable, PE-50 conduit is inserted into neck main artery, and presses with YP-100
Force snesor is connected, the variation of blood pressure after record administration.System arterial pressure and heart rate data mainly pass through Chengdu Tai Meng BL-420F
Biological recorder system handling averagely obtains.100 μ L of medical intravenous per injection is injected in 10~15 seconds and is completed.
The experimental result that morphine, hybrid peptide 3 and 4 pair Rat Cardiovascular act on is as shown in FIG. 11 and 12 (in Figure 11 and 12Indicate morphine,Indicate hybrid peptide 3,Indicate hybrid peptide 4), intravenous injection 1-10nmol dosage
Coffee, hybrid peptide 3 and 4 significantly reduce rat system arterial pressure, and are in dose dependent.However hybrid peptide 3 under all concentration
The effect of arterial pressure is reduced significantly lower than the morphine under corresponding concentration with 4.In addition, intravenous injection 1-10nmol dosage
The dose-dependent heart rate for reducing rat of coffee, hybrid peptide 3 and 4.It is similar with system arterial pressure, hybrid peptide 3 and 4 pair under all concentration
The effect that rat heart rate reduces is significantly lower than the morphine under corresponding concentration.Should the result shows that, hybrid peptide 3 and 4 pair is in body-centered blood vessel
The function and effect of system are significantly lower than morphine, that is, have the advantages that lower cardiovascular side effects.
In conclusion the cyclisation heterozygosis that the enkephalins of multidigit point modification of the present invention is mutually coupled with neurotensin (8-13)
Peptide is to repair methionine/leucine enkephalin amino acid sequence " Tyr-Gly-Gly-Phe-Met/Leu " by multidigit point
Decorations obtain " Dmt-Gly-c (Cys-NMePhe-Met-Cys) " and " Dmt-Gly-c (Cys-NMePhe-Leu-Cys) " with cyclisation
Amino acid residue sequence passes through the amino acid sequence " Arg-Arg-Pro-Tyr-Ile-Leu " of neurotensin (8-13) more
Site is modified to obtain " NMeArg-Lys-Pro-Trp-Tle-Leu " amino acid residue sequence, using intermediate connexon " Gly " or
Two parts amino acid residue sequence is mutually coupled by " D-Ala ", constructs a kind of new and effective hybrid peptide.By the first sulphur ammonia of hybrid peptide
Be added among the modification sequence of acid/leucine enkephalin and neurotensin (8-13) small molecule Amino acid linker " Gly " or
" D-Ala " can be improved the flexible conformation of hybrid peptide, retain methionine/leucine enkephalin and neurotensin (8-13)
The bioactivity of two parts modification sequence.Modified by multidigit point unnatural amino acid, the introducing of space connexon " D-Ala " with
And polypeptide cyclisation can significantly increase the resistance to enzymolysis ability of hybrid peptide.Moreover, part neurotensin (8-13) in hybrid peptide
It can reduce the adverse side effects such as analgesia tolerance and the angiocarpy of opioid drug, solve the resistance to enzymolysis energy of existing opioid drug
Power is poor, and analgesic activities are lower and the duration is shorter, and anti-neuropathic pain is ineffective, and has analgesia tolerance and angiocarpy
The problem of system side effect.
Tested by vitro biological stability, analgesia with Acute brain block test, anti-neurogenic pain activity experiment with
And in body Blood Pressure Experiment, pharmacological activity identification is carried out to the hybrid peptide that the present invention synthesizes.The result shows that hybrid peptide of the invention
Resistance to enzymolysis ability with higher.By central administration, hybrid peptide 1-4 in hot tail-flick test there is efficient analgesia to live
Property.Moreover, hybrid peptide 3 and 4 has peripherally administered efficient analgesic effect, and significant anti-neuropathic pain activity.In addition, miscellaneous
The medicine analgesic tolerance side effect for closing peptide 3 and 4 significantly reduces, and especially hybrid peptide 3 is with no analgesia tolerance characteristic, and it is to painstaking effort
The side effect of guard system is significantly reduced.Therefore, hybrid peptide of the invention is preparing efficient, low analgesia tolerance and cardiovascular secondary work
It is had potential application in terms of polypeptide analgesic.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811126681.0A CN109232748B (en) | 2018-09-26 | 2018-09-26 | Cyclic hybrid peptides conjugated with multi-site modified enkephalins and neurotensin (8-13) and their synthesis methods and applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811126681.0A CN109232748B (en) | 2018-09-26 | 2018-09-26 | Cyclic hybrid peptides conjugated with multi-site modified enkephalins and neurotensin (8-13) and their synthesis methods and applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109232748A CN109232748A (en) | 2019-01-18 |
| CN109232748B true CN109232748B (en) | 2019-06-11 |
Family
ID=65057515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811126681.0A Active CN109232748B (en) | 2018-09-26 | 2018-09-26 | Cyclic hybrid peptides conjugated with multi-site modified enkephalins and neurotensin (8-13) and their synthesis methods and applications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109232748B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113968902B (en) * | 2020-07-25 | 2023-05-26 | 兰州大学 | Leucine-enkephalin analogue, and preparation method and application thereof |
| CN119661638B (en) * | 2024-11-22 | 2025-07-18 | 象山县第一人民医院医疗健康集团(宁波市第四医院、宁波市第四医院医院管理研究所) | A polypeptide for repairing nerve damage, preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1423559A (en) * | 2000-02-08 | 2003-06-11 | 欧罗赛铁克股份有限公司 | Controlled-release compositions containing opioid agonist and antagonist |
| CN107964047A (en) * | 2017-12-18 | 2018-04-27 | 哈尔滨工业大学 | Chimeric peptide and its synthetic method and application based on Tyr-Pro-Trp-Phe-NH2 and neurotensin (8-13) |
-
2018
- 2018-09-26 CN CN201811126681.0A patent/CN109232748B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1423559A (en) * | 2000-02-08 | 2003-06-11 | 欧罗赛铁克股份有限公司 | Controlled-release compositions containing opioid agonist and antagonist |
| CN107964047A (en) * | 2017-12-18 | 2018-04-27 | 哈尔滨工业大学 | Chimeric peptide and its synthetic method and application based on Tyr-Pro-Trp-Phe-NH2 and neurotensin (8-13) |
Non-Patent Citations (1)
| Title |
|---|
| 内源性阿片肽系统免疫调节功能的研究进展;王玉秀等;《中国临床康复》;20030515;第7卷(第10期);摘要、第1558页第1.1及1.5节 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109232748A (en) | 2019-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69230610T2 (en) | Cyclic backbone peptides, their preparation and pharmaceutical compositions containing them | |
| CN110194785B (en) | Multi-target peptide molecule of opioid and neuropeptide FF receptor and preparation and application thereof | |
| AU750387B2 (en) | Novel conjugates of opioids and endogenous carriers | |
| CN102850431B (en) | Chimeric Peptide Based on Opioid Peptide Biphalin and Neuropeptide FF and Its Synthesis and Application | |
| US6602981B2 (en) | Antinociceptive agent derivative | |
| EP0125469A1 (en) | Conformationally constrained cyclic enkephalin analogs with delta receptor specificity | |
| CN109232748B (en) | Cyclic hybrid peptides conjugated with multi-site modified enkephalins and neurotensin (8-13) and their synthesis methods and applications | |
| US10428115B2 (en) | Dynorphin A analogs with bradykinin receptors specificity for modulation of neuropathic pain | |
| JPH08511541A (en) | Anti-inflammatory compositions and methods for DES-TYR dynorphin and analogs | |
| CN103012596B (en) | Endomorphin-derived peptide with blood-brain barrier permeability as well as synthesis and application of endomorphin-derived peptide | |
| CN109232747B (en) | Cyclized hybrid peptide of dynorphin A (1-8) coupled with neurotensin (8-13) and its synthesis method and application | |
| CN107964047B (en) | Chimeric peptide and its synthetic method based on Tyr-Pro-Trp-Phe-NH2 and neurotensin (8-13) and application | |
| CN1307900A (en) | Application of tigroid spider toxic extract in preparing analgesic | |
| US20160361378A1 (en) | Multivalent/multifunctional ligands with agonist activities at opioid receptors and antagonist activities at nk1 receptor for relief of pain | |
| CN101724026B (en) | A kind of melanocortin analogue and its preparation method and application | |
| CN100378126C (en) | C-terminally modified endomorphin1 | |
| EP1831244A2 (en) | Dermorphin analogs with analgesic activity | |
| CN102250251A (en) | Polyethylene glycol derivative of enkephalin analogue | |
| CN115073556A (en) | Opioid/neuropeptide FF receptor multi-target cyclic peptide molecule and preparation and application thereof | |
| CN112961249B (en) | Bifunctional peptide based on opioid peptide and cannabis peptide, and preparation method and application thereof | |
| CN115925801A (en) | A Class of Heteropolypeptides Based on Small Molecule Opioid and Neuropeptide FF and Its Preparation and Application | |
| CN118515729A (en) | Design, preparation and application of a new class of chimeric peptides and their analogs based on Kappa opioid peptide agonists | |
| CN118834271A (en) | Cyclic hexapeptide analogue containing aromatic structure amino acid at 3 sites and preparation and application thereof | |
| CN109021117B (en) | Opioid and neuropeptide FF receptor multi-target molecule BN-9 analogue, and preparation method and application thereof | |
| CN111363012B (en) | Cyclic endomorphin-1 analogs with enzymatic stability and analgesic activity and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210121 Address after: Building 9, accelerator, 14955 Zhongyuan Avenue, Songbei District, Harbin City, Heilongjiang Province Patentee after: INDUSTRIAL TECHNOLOGY Research Institute OF HEILONGJIANG PROVINCE Address before: 150001 No. 92 West straight street, Nangang District, Heilongjiang, Harbin Patentee before: HARBIN INSTITUTE OF TECHNOLOGY |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230302 Address after: 150027 Room 412, Unit 1, No. 14955, Zhongyuan Avenue, Building 9, Innovation and Entrepreneurship Plaza, Science and Technology Innovation City, Harbin Hi tech Industrial Development Zone, Heilongjiang Province Patentee after: Heilongjiang Industrial Technology Research Institute Asset Management Co.,Ltd. Address before: Building 9, accelerator, 14955 Zhongyuan Avenue, Songbei District, Harbin City, Heilongjiang Province Patentee before: INDUSTRIAL TECHNOLOGY Research Institute OF HEILONGJIANG PROVINCE |